Barron's Logo

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/novartis-stock-price-ceo-cancer-drug-medicare-e9b0fcb7

Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations

By
Josh Nathan-Kazis
  • Order Reprints
  • Print Article

Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will make them no longer worthwhile for the company, according to CEO Vas Narasimhan.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.